NAC, Physostigmine & Neostigmine: Their efficacy as antidote - By RxVichu!!! :) :)

rxvichu 6,307 views 25 slides Jan 27, 2018
Slide 1
Slide 1 of 25
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25

About This Presentation

This powerpoint encompasses some details regarding the pharmacology, ADRs, interactions, dosage regimens and special points that need to be kept in mind, while using the antidotes "ACETYLCYSTEINE, PHYSOSTIGMINE & NEOSTIGMINE".

Do go through this, and let me know your reviews.

Regard...


Slide Content

NAC, PHYSOSTIGMINE & NEOSTIGMINE – THEIR EFFICACY AS ANTIDOTE PREPARED BY: VISHNU.R.NAIR, 5 TH YEAR PHARM.D, NATIONAL COLLEGE OF PHARMACY, KERALA.

GENERAL INTRODUCTION: An antidote is a “drug, chelating substance/ a chemical that counteracts(neutralizes) the effects of another drug/ poison” Although there are dozens of different antidotes  some may counteract only one particular drug; whereas others(like charcoal) may help to reduce the toxicity of numerous drugs. Most antidotes are not 100% effective, and fatalities may still occur even when an antidote has been given. Here, I will present the details of antidotes “ACETYLCYSTEINE(NAC)”, “PHYSOSTIGMINE & NEOSTIGMINE”. HAPPY READING!!!

N-ACETYLCYSTEINE AS ANTIDOTE: A DEEP INSIGHT

PHARMACOLOGY: NAC  binds to highly reactive electrophilic metabolism intermediates  detoxifies them Drug  enhances reduction of toxic intermediate (NAPQI) to parent “Acetaminophen” Drug  reduces severity of liver injury via the following methods : Improves blood flow Improves oxygen delivery Modifies cytokine production Scavenges free radicals / O2

Drug  most effective in preventing acetaminophen-induced liver injury, when given in the EARLY COURSE OF INTOXICATION(8-10 hours of poison ingestion) 2. INDICATIONS: NAC may be used as antidote in the following conditions: Acetaminophen overdose Based on case reports/ investigational reports: CCl4 Chloroform Acrylonitrile Doxorubicin

e. Arsenic f. Gold g. Amanitin mushroom h. CO i. Chromium j. Cyanide k. Nitrofurantoin l. Paraquat m. Phosphide n. Methyl mercury poisoning.

iii. NAC also finds application in the following conditions:’ Pennyroyal oil poisoning Clove oil poisoning Cisplatin nephrotoxicity Prevention of radiocontrast-induced nephropathy Pyroglutamic aciduria(5-oxoprolinuria) 3. CONTRAINDICATIONS: Known acute hypersensitivity/ IgE -mediated anaphylaxis Anaphylactoid reactions.

4. ADRs: NAC  has offensive odor  can induce emesis, when given orally With rapid i.v administration  the following may occur: Flushing Rash Angioedema Hypotension Bronchospasm.

5. DRUG/ LABORATORY INTERACTIONS: Activated charcoal  adsorbs NAC  not clinically significant NAC  prolongs measured PT & INR. 6. DOSAGE & METHOD OF ADMINISTRATION: NAC  can be given as oral/i.v For treatment of complicated poisonings (within 8 hours of ingestion)  20-hour treatment regimen is followed. After 2-hour regimen  if acetaminophen is detected/ Hepatic aminotransferase levels are high  continue giving NAC at maintenance dose, unless issue is resolved.

FOR ORAL ADMINISTRATION: Loading dose: 140 mg/kg, diluted in juice/soda(to enhance palatability) Maintenance dose: 70 mg/kg; every 4 hours. FOR I.V ADMINISTRATION: Give loading dose of 150 mg/kg(max. dose: 15 g) over 1 hour  then give 50 mg/kg every 4 hours  then 100 mg/kg over 6 hours. If I.V NAC is not available  administer ORAL NAC FORM(via I.V ROUTE) , using an in-line micropore filter.

7. SPECIAL NOTES: If anaphylactoid reactions occur with I.V administration  STOP INFUSION IMMEDIATELY  Treat with DIPHENHYDRAMINE Provide EPINEPHRINE for more serious reactions (Shock, bronchoconstriction) Once symptoms resolve  restart the infusion at a slower rate Patients, with history of asthma  may be at a higher risk of developing anaphylactoid reactions Drug  comes under FDA PREGNANCY CATEGORY “B” (No evidence of teratogenicity)

PHYSOSTIGMINE & NEOSTIGMINE : A DEEP INSIGHT

PHARMACOLOGY: PHYSOSTIGMINE & NEOSTIGMINE are carbamates Drugs  reversibly inhibit ACETYLCHOLINESTERASE  increase ACh  stimulate muscarinic & nicotinic receptors Physostigmine  has TERTIARY AMINE STRUCTURE  penetrates BBB  exerts cholinergic effects in the CNS Neostigmine  is a QUATERNARY AMMONIUM COMPOUND  doesn’t cross BBB FOR PHYSOSTIGMINE: Onset of action: 3-8 mins b. Duration of action: 30-90 mins FOR NEOSTIGMINE: a. Onset of action: 7-11 mins b. Duration of action: 1-2 hours.

2. INDICATIONS: FOR PHYSOSTIGMINE: To treat the following manifestations of anticholinergic syndromes from BENZTROPINE, ATROPINE, JIMSON WEED(DATURA), DIPHENHYDRAMINE: Agitated delirium Urinary retention Severe sinus tachycardia Hyperthermia without sweating

Indications, based on ANECDOTAL CASE REPORTS: GAMMA-HYDROXY BUTYRATE(GHB) Baclofen Antipsychotics(olanzapine, clozapine, quetiapine) To diagnostically differentiate between functional psychosis(infectious encephalitis) from anticholinergic delusions. Non-specific uses include arousal in patients with the following toxicities: Opioids c. Sedative-hypnotic intoxication BZDs d. Ketamine/ Propofol induced sedation. b. FOR NEOSTIGMINE: To reverse effects of non-depolarizing neuromuscular blockers to treat delirium and coma

3. CONTRAINDICATIONS: NEVER USE PHYSOSTIGMINE AS AN ANTIDOTE for TCA POISONING !!!  may lead to worsening of cardiac conduction disturbances, bradyarrhythmias , asystoles & seizure aggravation. NEVER USE ALONG WITH DEPOLARIZING NEUROMUSCULAR BLOCKERS Known hypersensitivity to drug, benzyl alcohol/ bisulfite Asthma Peripheral vascular disease Intestinal & bladder blockade Parkinsonism AV block.

4. ADRs: Bradycardia Heart block(AV) Seizures(with rapid administration/ high drug doses) Nausea & vomiting Bronchospasm Diarrhea Bronchorrhea Hypersalivation Fasciculations Muscle weakness.

5. DRUG/ LABORATORY INTERACTIONS: Drug  potentiate activity of agents metabolized by cholinesterase enzyme (like Depolarizing NMBs, OP, Carbamates, other cholinergic agents,etc ) Neostigmine  inhibits/ reverses actions of non-depolarizing NMBs ( pancuronium , vecuronium) Drug + TCA / Beta-adrenergic antagonists / calcium antagonist overdoses  cause additive cardiac conduction defects.

6. DOSAGE & METHOD OF ADMINISTRATION: Patient should be on a cardiac monitor (in case of bradyarrhythmia) FOR PHYSOSTIGMINE: Adult dose: Give 0.5-1 mg(i.v) slowly( diluted in 10 ml. of D5W/ NS) , over 2-5 mins  observe for improvement/ ADRs(bradycardia/ heart block)  if there is no response  give additional 0.5 mg doses, at 5-10 minute intervals, with a maximum total dose of 2 mg, over the first hour.

B. Pediatric dose: 0.01 mg/kg(do not exceed 0.5 mg) --< repeat as needed, upto a maximum dose of 0.04 mg/kg(/ 2 mg in first hour) ATROPINE should be kept nearby, to reverse excessive muscarinic stimulation, with doses of 1-4 mg(adults) & 1 mg(in children) Never give physostigmine as INTRAMUSCULAR injection. Physostigmine  has short duration of action  repeat doses every 30-60 minutes(as required).

FOR NEOSTIGMINE: Give 0.5-2 mg slow I.V PUSH (0.025-0.08 mg/kg for children)  repeat doses as required (Maximum dose: 5 mg) Pre-medicate with GLYCOPYRROLATE (For adults: 0.2- 0.6 mg, for children : 0.004-0.02 mg/kg), OR ATROPINE (For adults: 0.6-1.2 mg; for children: 0.01- 0.04 mg/kg) Administer ATROPINE/ GLYCOPYRROLATE before/ simultaneously with NEOSTIGMINE , to prevent muscarinic effects(bradycardia, secretions).

7. SPECIAL NOTES: Drug  comes under FDA PREGNANCY CATEGORY “C” Transient weakness  noted in NEONATES, whose mothers were treated with PHYSOSTIGMINE for myasthenia gravis.

REFERENCES/ BIBLIOGRAPHY: Algren DA. Review of N-acetylcysteine for the treatment of acetaminophen(paracetamol) toxicity in pediatrics. Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Geneva,2008. http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021539slbl.pdf Schmidt LE. Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in the treatment of paracetamol overdose. Clin Toxicol 2013;51(6):467-72.

4. Schwartz E, Cohn B. Systematic Review Snapshot: Is intravenous acetylcysteine more effective than oral administration in the prevention of hepatotoxicity in acetaminophen overdose? Ann Emerg Med 2014; 63(1): 79-80. 5. Burns MJ et al. A Comparison if physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374-81. 6. Howland MA. “Antidotes in Depth(A12): Physostigmine Salicylate:. Goldfrank’s Toxicologic Emergencies, Nelson LS et al, editors, 9 th Edition, McGraw-Hill, 2011. Pages 759-62. 7. Schneir AB et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med 2003; 42: 14-19. 8. Seifert SA, “Chapter 67:Physostigmine and Pyridostigmine.” Medical Toxicology 3 rd Edition, Dart RC et al, editors. Philadelphia:Lippincott , Williams & Wilkins, 2004: 232-36

THANK YOU!!!!!